Literature DB >> 20127253

The role of TP53 and p21 gene polymorphisms in breast cancer biology in a well specified and characterized German cohort.

Florian Ebner1, Elisabeth Schremmer-Danninger, Joachim Rehbock.   

Abstract

OBJECTIVE: Abrogation of the function of TP53 gene is supposed to lead to a more aggressive breast cancer phenotype that produces a less favorable clinical outcome. The p21 gene on chromosome 6p21.2 can be stimulated by an activated TP53 gene. A product of transcription, the p21 protein, an inhibitor of cyclin-dependent kinases, has its function in gene repair and angiogenesis during cell division, and can regulate apoptosis. The purpose of this analysis was to examine for an association between the genotypes measured on two single nucleotide polymorphisms (SNPs) located within the TP53 and p21 genes.
METHODS: In a clinical epidemiological case-control study, 814 individuals were recruited. 550 samples (275 cases/275 control) of peripheral blood obtained from women (aged 22-87 years) with breast cancer and from healthy women (aged 23-87 years) were genotyped for frequencies of the following gene variances: R72P/rs1042522 (gene TP53) and S31R/ss4388499 (gene p21).
RESULTS: For the variance in gene TP53 no significant differences between the control group and women with breast cancer could be estimated. For the variance in gene p21 a statistically significant association between the SNP measured within p21 and breast cancer status was observed. The odds ratio for the increased risk for those carrying the CA genotype as opposed to the CC genotype is 1.74 (95% confidence ratio = 1.00-3.05).
CONCLUSION: Despite this finding p21 does not appear to act as an exclusive prognostic marker for breast cancer disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127253     DOI: 10.1007/s00432-010-0788-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  43 in total

1.  Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer.

Authors:  R Bahl; S Arora; N Nath; M Mathur; N K Shukla; R Ralhan
Journal:  Oncogene       Date:  2000-01-20       Impact factor: 9.867

2.  K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.

Authors:  A Castells; P Puig; J Móra; J Boadas; L Boix; E Urgell; M Solé; G Capellà; F Lluís; L Fernández-Cruz; S Navarro; A Farré
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

3.  High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.

Authors:  A Lavigueur; V Maltby; D Mock; J Rossant; T Pawson; A Bernstein
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

4.  Waf-1 (p21) and p53 polymorphisms in breast cancer.

Authors:  Channa Keshava; Bonnie L Frye; Mary S Wolff; Erin C McCanlies; Ainsley Weston
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-01       Impact factor: 4.254

5.  Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer.

Authors:  Brenda L Powell; Iris L van Staveren; Paul Roosken; Fabienne Grieu; Els M J J Berns; Barry Iacopetta
Journal:  Carcinogenesis       Date:  2002-02       Impact factor: 4.944

6.  WAF1 genotype and endometrial cancer susceptibility.

Authors:  T Hachiya; Y Kuriaki; Y Ueoka; J Nishida; K Kato; N Wake
Journal:  Gynecol Oncol       Date:  1999-02       Impact factor: 5.482

7.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice.

Authors:  Ruchika Kaul; Sujoy Mukherjee; Farid Ahmed; Manoj Kumar Bhat; Rishiraj Chhipa; Sanjeev Galande; Samit Chattopadhyay
Journal:  Int J Cancer       Date:  2003-02-20       Impact factor: 7.396

9.  p53 polymorphisms and haplotypes in breast cancer.

Authors:  A Själander; R Birgander; G Hallmans; S Cajander; P Lenner; L Athlin; G Beckman; L Beckman
Journal:  Carcinogenesis       Date:  1996-06       Impact factor: 4.944

10.  High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  K H Buetow; M Edmonson; R MacDonald; R Clifford; P Yip; J Kelley; D P Little; R Strausberg; H Koester; C R Cantor; A Braun
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  7 in total

1.  Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.

Authors:  Hongtao Cheng; Biao Ma; Ran Jiang; Wei Wang; Hui Guo; Na Shen; Dapeng Li; Qunzi Zhao; Rui Wang; Pengfei Yi; Yue Zhao; Zeming Liu; Tao Huang
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

2.  Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Authors:  Patricia Rodrigues; Jessica Furriol; Eduardo Tormo; Sandra Ballester; Ana Lluch; Pilar Eroles
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

3.  Aberrant promoter hypermethylation of p21 (WAF1/CIP1) gene and its impact on expression and role of polymorphism in the risk of breast cancer.

Authors:  Marjan Askari; Ranbir Chander Sobti; Mohsen Nikbakht; Suresh C Sharma
Journal:  Mol Cell Biochem       Date:  2013-09-05       Impact factor: 3.396

4.  TP53 gene rs1042522 allele G decreases neuroblastoma risk: a two-centre case-control study.

Authors:  Jiao Zhang; Yang Yang; Wenya Li; Lizhao Yan; Da Zhang; Jing He; Jiaxiang Wang
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

5.  p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies.

Authors:  Brehima Diakite; Yaya Kassogue; Guimogo Dolo; Jun Wang; Erin Neuschler; Oumar Kassogue; Mamadou L Keita; Cheick B Traore; Bakarou Kamate; Etienne Dembele; Sellama Nadifi; Robert L Murphy; Seydou Doumbia; Lifang Hou; Mamoudou Maiga
Journal:  BMC Med Genet       Date:  2020-10-19       Impact factor: 2.103

6.  p53 codon 72 polymorphism and breast cancer risk: A meta-analysis.

Authors:  Jing Hou; Yuan Jiang; Wenru Tang; Shuting Jia
Journal:  Exp Ther Med       Date:  2013-03-20       Impact factor: 2.447

7.  Genetic variants in genes related to inflammation, apoptosis and autophagy in breast cancer risk.

Authors:  Johanna M Schuetz; Anne Grundy; Derrick G Lee; Agnes S Lai; Lindsay C Kobayashi; Harriet Richardson; Jirong Long; Wei Zheng; Kristan J Aronson; John J Spinelli; Angela R Brooks-Wilson
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.